Company / Revenue
Amylyx Pharmaceuticals, Inc. Revenue History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
-
FY2025
5-year range
$0 / $380.8M
FY2021-FY2025
Trend
-100.0%
vs FY2024
Sector context
#148 of 155
Health Care
What the data says
Declined from $381M to $0 over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 5% in Health CareTop 95% of 155
▼
Key checks
Key Insights
- In FY2025, revenue decreased 100.0% year-over-year.
- Peak revenue was recorded in FY2023.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0 | -100.0% |
| FY2024 | $87.4M | -77.1% |
| FY2023 | $380.8M | +1612.9% |
| FY2022 | $22.2M | +7700.0% |
| FY2021 | $285.0K | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026